- Hancock Jaffe Laboratories Inc HJLI will change its name to enVVeno Medical Corporation and start under a new ticker, "NVNO," from October 1.
- The Company will also narrow its strategic focus to reflect its decision to go all-in on the VenoValve and treat venous disease.
- Related: Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device.
- Hancock Jaffe is ready to begin enrollment for the U.S. pivotal trial for the VenoValve, a potential treatment for deep venous Chronic Venous Insufficiency (CVI).
- Also Read: Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve.
- Price Action: HJLI stock traded 2.08% lower at $9.40 premarket on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
